Skip to main content
Erschienen in: Clinical Journal of Gastroenterology 5/2019

02.04.2019 | Case Report

A case of extrahepatic bile duct cancer with distant metastases showing pathological complete response to treatment combining gemcitabine and cisplatin

verfasst von: Kai Adachi, Kosuke Okuwaki, Ryo Nishiyama, Mitsuhiro Kida, Hiroshi Imaizumi, Tomohisa Iwai, Hiroshi Yamauchi, Toru Kaneko, Rikiya Hasegawa, Eiji Miyata, Yusuke Kumamoto, Wasaburo Koizumi

Erschienen in: Clinical Journal of Gastroenterology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

The patient was a 69-year-old female with a chief complaint of yellow staining of her urine. A detailed physical examination and laboratory tests were carried out, and as a result, her condition was diagnosed as unresectable advanced extrahepatic cholangiocarcinoma with liver metastases. Chemotherapy using gemcitabine + cisplatin was initiated, and computed tomography after six cycles revealed that the liver metastases had disappeared, and that a partial response was achieved in the primary tumor. After tan cycles, a pylorus-preserving pancreaticoduodenectomy was performed as conversion surgery, and as a result, a pathological complete response was achieved in the primary tumor. After the primary lesion was resected, we were able to start an adjuvant chemotherapy immediately. Approximately 19 months have passed since the surgery, and the patient is currently alive and recurrence-free. If an improvement of the outcomes of chemotherapy in unresectable advanced biliary tract carcinomas is achieved in the future, there could be an increase in the number of treatment-responsive cases like the one reported in this study. Accumulating a large number of cases successfully treated by conversion surgery, and conducting a detailed analysis of the postoperative course, may help design adequate treatment strategies.
Literatur
1.
Zurück zum Zitat Miyasaka S, Ishihara S, Horiguchi A, et al. Biliary tract cancer treatment: 5584 results from the Biliary Tract Cancer Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg. 2009;16:1–7.CrossRef Miyasaka S, Ishihara S, Horiguchi A, et al. Biliary tract cancer treatment: 5584 results from the Biliary Tract Cancer Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg. 2009;16:1–7.CrossRef
2.
Zurück zum Zitat Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.CrossRef Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.CrossRef
3.
Zurück zum Zitat Rho YS, Barrera I, Metrakos P, et al. Complete resolution of metastatic gallbladder cancer after standard gemcitabine-cisplatin combination therapy. Cureus. 2015;17:e415. Rho YS, Barrera I, Metrakos P, et al. Complete resolution of metastatic gallbladder cancer after standard gemcitabine-cisplatin combination therapy. Cureus. 2015;17:e415.
4.
Zurück zum Zitat Kato A, Shimizu H, Ohtsuka M, et al. Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol. 2015;22(Suppl 3):S1093–9.CrossRef Kato A, Shimizu H, Ohtsuka M, et al. Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol. 2015;22(Suppl 3):S1093–9.CrossRef
5.
Zurück zum Zitat Sharma A, Mohanti B, Raina V, et al. A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer. Cancer Chemother Pharmacol. 2010;65:497–502.CrossRef Sharma A, Mohanti B, Raina V, et al. A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer. Cancer Chemother Pharmacol. 2010;65:497–502.CrossRef
6.
Zurück zum Zitat Moussata D, Bessayah A, Chauvenet M, et al. A pathologic complete response in the surgical specimen after systemic chemotherapy for a gallbladder carcinoma. Cancer Res. 2012;5:106–8. Moussata D, Bessayah A, Chauvenet M, et al. A pathologic complete response in the surgical specimen after systemic chemotherapy for a gallbladder carcinoma. Cancer Res. 2012;5:106–8.
7.
Zurück zum Zitat Lim JH, Ryu JK, Choi YJ, et al. A case of common bile duct cancer that completely responded to combination chemotherapy of gemcitabine and TS-1. Gut Liver. 2013;7:371–6.CrossRef Lim JH, Ryu JK, Choi YJ, et al. A case of common bile duct cancer that completely responded to combination chemotherapy of gemcitabine and TS-1. Gut Liver. 2013;7:371–6.CrossRef
8.
Zurück zum Zitat Yoshida R, Matsuda T, Watanabe T, et al. A case of gallbladder cancer which completely responded to gemcitabine. Gan To Kagaku Ryoho. 2010;37:1771–3.PubMed Yoshida R, Matsuda T, Watanabe T, et al. A case of gallbladder cancer which completely responded to gemcitabine. Gan To Kagaku Ryoho. 2010;37:1771–3.PubMed
9.
Zurück zum Zitat Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreatico-duodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335–9.CrossRef Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreatico-duodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335–9.CrossRef
10.
Zurück zum Zitat Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer. A comparative multicenter study in Japan. Br J Cancer. 2010;103:469–74.CrossRef Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer. A comparative multicenter study in Japan. Br J Cancer. 2010;103:469–74.CrossRef
11.
Zurück zum Zitat Morizane C, Okusaka T, Mizusawa J, et al. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci. 2013;104:1211–6.CrossRef Morizane C, Okusaka T, Mizusawa J, et al. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci. 2013;104:1211–6.CrossRef
12.
Zurück zum Zitat Mizusawa J, Morizane C, Okusaka T, et al. Randomized phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT). Jpn J Clin Oncol. 2016;46:385–8.CrossRef Mizusawa J, Morizane C, Okusaka T, et al. Randomized phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT). Jpn J Clin Oncol. 2016;46:385–8.CrossRef
13.
Zurück zum Zitat Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomized, phase 3 study. Lancet Oncol. 2012;13:181–8.CrossRef Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomized, phase 3 study. Lancet Oncol. 2012;13:181–8.CrossRef
14.
Zurück zum Zitat Arai Y, Totoki Y, Hosoda F, et al. Treatment with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074 effectively suppressed transformation. Hepatology. 2014;59:1427–34.CrossRef Arai Y, Totoki Y, Hosoda F, et al. Treatment with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074 effectively suppressed transformation. Hepatology. 2014;59:1427–34.CrossRef
15.
Zurück zum Zitat Sia D, Losic B, Moeini A, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun. 2015;6:6087.CrossRef Sia D, Losic B, Moeini A, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun. 2015;6:6087.CrossRef
16.
Zurück zum Zitat Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59:1427–34.CrossRef Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59:1427–34.CrossRef
17.
Zurück zum Zitat Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3:636–47.CrossRef Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3:636–47.CrossRef
18.
Zurück zum Zitat Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRef Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRef
19.
Zurück zum Zitat Okusaka T, Ikeda M, Fukutomi A, et al. Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Cancer Sci. 2014;105:1321–6.CrossRef Okusaka T, Ikeda M, Fukutomi A, et al. Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Cancer Sci. 2014;105:1321–6.CrossRef
20.
Zurück zum Zitat Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRef Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRef
21.
Zurück zum Zitat Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548–54.CrossRef Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548–54.CrossRef
22.
Zurück zum Zitat Ueno H, Ikeda M, Ueno M, et al. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2016;77:595–603.CrossRef Ueno H, Ikeda M, Ueno M, et al. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2016;77:595–603.CrossRef
23.
Zurück zum Zitat Park JK, Paik WH, Ryu JK, et al. Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1446 patients from the pancreatic cancer cohort in a single institution. PLoS One. 2013;8:e78977.CrossRef Park JK, Paik WH, Ryu JK, et al. Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1446 patients from the pancreatic cancer cohort in a single institution. PLoS One. 2013;8:e78977.CrossRef
24.
Zurück zum Zitat Choi M, Heibrun LK, Venkatramanamoorthy R, et al. Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemoradiotherapy for locally advanced pancreatic cancer. Am J Clin Oncol. 2010;33:257–61.PubMed Choi M, Heibrun LK, Venkatramanamoorthy R, et al. Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemoradiotherapy for locally advanced pancreatic cancer. Am J Clin Oncol. 2010;33:257–61.PubMed
Metadaten
Titel
A case of extrahepatic bile duct cancer with distant metastases showing pathological complete response to treatment combining gemcitabine and cisplatin
verfasst von
Kai Adachi
Kosuke Okuwaki
Ryo Nishiyama
Mitsuhiro Kida
Hiroshi Imaizumi
Tomohisa Iwai
Hiroshi Yamauchi
Toru Kaneko
Rikiya Hasegawa
Eiji Miyata
Yusuke Kumamoto
Wasaburo Koizumi
Publikationsdatum
02.04.2019
Verlag
Springer Japan
Erschienen in
Clinical Journal of Gastroenterology / Ausgabe 5/2019
Print ISSN: 1865-7257
Elektronische ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-019-00972-0

Weitere Artikel der Ausgabe 5/2019

Clinical Journal of Gastroenterology 5/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.